Although four weekly infusions of apoA-I could not prevent the recurrence of cardiovascular events after acute myocardial infarction through 90 days[46], intravenous administration of apoA-I increases cholesterol efflux capacity[47, 48], and displays a promising outcome in inducing regression of coronary atherosclerosis[12]. The gene discussed is APOA1; the disease is acute myocardial infarction.